Pages that link to "Q61853643"
Jump to navigation
Jump to search
The following pages link to Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters (Q61853643):
Displaying 17 items.
- Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab (Q33573621) (← links)
- Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials (Q33625546) (← links)
- Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications (Q34099814) (← links)
- Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab (Q34199603) (← links)
- Structural basis of IL-23 antagonism by an Alphabody protein scaffold (Q34445379) (← links)
- Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab (Q34502118) (← links)
- Preclinical development of AMG 139, a human antibody specifically targeting IL-23 (Q34795742) (← links)
- Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to date (Q36643600) (← links)
- Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis (Q37929165) (← links)
- Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab. (Q40060286) (← links)
- Diagnostic utility of Ki-67 and Cyclin D1 immunostaining in differentiation of psoriasis vs. other psoriasiform dermatitis (Q42532658) (← links)
- Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis (Q47171494) (← links)
- Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab). (Q48239956) (← links)
- Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows (Q58785751) (← links)
- Exacerbation of Infliximab-Induced Palmoplantar Psoriasis Under Ustekinumab Therapy in a Patient With Ankylosing Spondylitis (Q84983874) (← links)
- The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease (Q92276623) (← links)
- Indirect Regulation and Equilibrium of p35 and p40 Subunits of Interleukin (IL)-12/23 by Ustekinumab in Psoriasis Treatment (Q92471867) (← links)